RTP Mobile Logo
Striving for Consensus on the Optimal Management of HER2-Positive Breast Cancer (Video Program)
Released April 2021

Featuring a roundtable discussion with Drs Virginia F Borges, Sara Hurvitz and Ian E Krop. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of breast cancer.

    LEARNING OBJECTIVES

    • Assess the key clinical variables that affect the use of preoperative therapy and the selection of specific therapeutic regimens for patients with HER2-overexpressing localized breast cancer, and integrate this information into treatment decision-making.
    • Evaluate published research data to guide the selection of adjuvant and/or extended-adjuvant therapy for patients with HER2-overexpressing localized breast cancer.
    • Implement a long-term clinical plan for the management of advanced HER2-positive breast cancer, incorporating existing and emerging targeted treatments.
    • Design an optimal approach to the care of patients with HER2-positive breast cancer and CNS metastases, considering the implications of prior therapeutic exposure, symptomatology and other factors.
    • Appraise available research data leading to the FDA approval of trastuzumab deruxtecan for HER2-positive metastatic breast cancer, and determine how this agent may be incorporated into clinical practice.
    • Consider the recent FDA approval of tucatinib with trastuzumab and capecitabine for previously treated advanced unresectable or metastatic HER2-positive breast cancer, including brain metastases, and identify patients who are appropriate candidates for treatment with this regimen.
    • Recognize the side effects associated with approved and investigational anti-HER2 agents, and use this information to develop supportive management plans for patients undergoing treatment for HER2-positive breast cancer.
    • Consider ongoing clinical research studies evaluating novel agents and treatment strategies under development for HER2-positive breast cancer, and counsel appropriate patients regarding the potential benefits of trial participation.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Audio Program: Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Video Program: Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of these CME activities, which includes participation in the evaluation components and short post-tests, enables the participant to earn up to 1.75 (audio) and 1.75 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, review the downloadable slide set, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/HER2BCSummit21/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/HER2BCSummit21/Video.

    Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/HER2BCSummit21/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/HER2BCSummit21.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Virginia F Borges, MD, MMSc
    Professor of Medicine with Tenure
    John C and Patricia Young-Connor Endowed Chair in Young Women’s Breast Cancer
    Deputy Head, Division of Medical Oncology
    Director, Breast Cancer Research Program and
    Young Women’s Breast Cancer Translational Program
    University of Colorado Cancer Center
    Aurora, Colorado

    Consulting Agreement: Seagen Inc; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Merck, Pfizer Inc, Seagen Inc.

    Sara Hurvitz, MD
    Professor of Medicine
    David Geffen School of Medicine at UCLA
    Director, Breast Cancer Clinical Research Program
    Co-Director, Santa Monica-UCLA Outpatient Oncology Practice
    Santa Monica, California

    Consulting Agreement (Stock Investment): NKMax America; Contracted Research: Ambrx Inc, Amgen Inc, Arvinas, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Dignitana, Genentech, a member of the Roche Group, GlaxoSmithKline, Immunomedics Inc, Lilly, MacroGenics Inc, Novartis, OBI Pharma Inc, Pfizer Inc, Pieris Pharmaceuticals Inc, Puma Biotechnology Inc, Radius Health Inc, Sanofi Genzyme, Seagen Inc, Zymeworks; Paid Travel: Lilly; Stocks (Spouse): IDEAL IMPLANT, ROMTech.

    Ian E Krop, MD, PhD
    Associate Chief, Division of Breast Oncology
    Dana-Farber Cancer Institute
    Associate Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, MacroGenics Inc; Contracted Research: Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Pfizer Inc, Taiho Oncology Inc; Data and Safety Board Monitoring Board/Committee: Merck, Novartis.

    EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc and Seagen Inc.

    Release date: April 2021
    Expiration date: April 2022

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):

Introduction

Management of HER2-positive early breast cancer

Selection and sequencing of therapies for HER2-positive metastatic breast cancer

Select publications